Schering-Plough Corp. and Merck and Co. Inc. late on Friday announced that the US Food and Drug Administration had approved Zetia as a stand-alone cholesterol-lowering treatment, as well as for use alongside any of the popular currently marketed statins.
Officials of a joint venture between the two New Jersey-based firms said that Zetia works by preventing the intestines from absorbing cholesterol, whereas statins inhibit the liver’s natural production of cholesterol.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!